scholarly journals Faculty Opinions recommendation of Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

2009 ◽  
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Cancer ◽  
Phase Iii ◽  
Advanced Stage ◽  
Phase Iii Trial ◽  
Treatment Regimens

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 149-155 ◽  
Author(s):  
M. A. Bookman ◽  
B. E. Greer ◽  
R. F. Ozols
Keyword(s):  
Ovarian Cancer ◽  
Surgical Outcomes ◽  
Gynecologic Cancer ◽  
Advanced Ovarian Cancer ◽  
Cytotoxic Agents ◽  
Phase Iii ◽  
Current Status ◽  
Standard Regimen ◽  
Phase Iii Trial ◽  
Optimal Therapy

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well-tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

2003 ◽  
Vol 13 (6) ◽  
pp. 735-740 ◽  
Author(s):  
M. A. Bookman ◽  
B. E. Greer ◽  
R. F. Ozols
Keyword(s):  
Ovarian Cancer ◽  
Surgical Outcomes ◽  
Gynecologic Cancer ◽  
Advanced Ovarian Cancer ◽  
Cytotoxic Agents ◽  
Phase Iii ◽  
Current Status ◽  
Standard Regimen ◽  
Phase Iii Trial ◽  
Optimal Therapy

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

Sign in / Sign up

Export Citation Format

Share Document